Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $35.00 price target on the stock.
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Rapport Therapeutics Announces Pricing of Initial Public Offering